MIDD innovations for paediatric rare disease drug development, addressing small populations and patient heterogeneity. Published Clin Pharmacol Ther, 2025
How a DRE-enabled patient swarm approach incorporates the patient voice into collaborative QSP model development for Parkinson's disease across academic centres
Data federation in a trusted research environment
This whitepaper covers the concept of data federation within a trusted research environment by using the example of Aridhia’s work with the PHEMS consortium.
Consideration of the Root Causes in Candidate Attrition During Oncology Drug Development
Oncology candidates fail at twice the rate of other therapeutic areas. This paper examines root causes of attrition from first-in-human through to registration.
Artificial Intelligence Opportunities to Guide Precision Dosing Strategies
How AI guides precision dosing, therapeutic drug monitoring, biomarker integration and individualised pharmacotherapy. Published J Pediatr Pharmacol Ther, 2024.
A modern curriculum for training scientists in model informed drug development
C-Path and partners report progress on an FDA-funded MIDD e-learning curriculum for regulatory scientists — published in Clinical Pharmacology & Therapeutics.
Implementing precision medicine with the Liver Cancer Collaborative
How the Liver Cancer Collaborative implemented precision medicine using the Aridhia DRE. A blueprint for governed, collaborative cancer research delivery.
How DRE connectivity enables platform trials. Shared infrastructure, governed multi-site data access, and adaptive trial design at scale.
Assessing the Aridhia DRE against the SATRE specification
This paper scores the DRE against the four sections of the SATRE specification and summarises some of the features that we believe contribute toward that score.
